X0306 4 2018-02-14 0 0001453593 Xtant Medical Holdings, Inc. XTNT 0001732521 Eggenberg Michael 664 CRUISER LANE BELGRADE MT 59714 1 0 1 0 Common Stock 2018-02-14 4 A 0 5126534 7.2 A 5287197 I See Footnotes Common Stock 2018-02-14 4 A 0 2905396 7.2 A 2973996 I See Footnotes Common Stock 2018-02-14 4 P 0 603687 7.2 A 5890884 I See Footnotes Common Stock 2018-02-14 4 P 0 342132 7.2 A 3316128 I See Footnotes Convertible Note 46.56 2018-02-14 4 D 0 33190000 46.56 D 2021-07-15 Common Stock 33190000 0 I See Footnotes Convertible Note 46.56 2018-02-14 4 D 0 18810000 46.56 D 2021-07-15 Common Stock 18810000 0 I See Footnotes Convertible Note 34.8 2018-02-14 4 D 0 1428553 34.8 D 2021-07-15 Common Stock 1428553 0 I See Footnotes Convertible Note 34.8 2018-02-14 4 D 0 809614 34.8 D 2021-07-15 Common Stock 809614 0 I See Footnotes These securities are held of record by ROS Acquisition Offshore LP ("ROS Acquisition"). OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of Advisors. These securities are held of record by OrbiMed Royalty Opportunities II, LP ("ORO II"). OrbiMed ROF II LLC ("ROF II") is the sole general partner of ORO II, and Advisors is the sole managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of Advisors. Each of ROS Acquisition, ORO II, Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. These convertible notes (collectively, the "Notes") were convertible into shares of common stock ("Shares") of the Issuer at any time prior to the close of business on the second business day immediately preceding July 15, 2021. However, the Notes were not convertible to the extent that such conversion would result in the holder of each Note or any of its affiliates being deemed to beneficially own in excess of 9.99% of the then-outstanding Shares. Gives effect to the 1:12 reverse stock split which occurred on February 14, 2018. On February 14, 2018, the Notes, plus accrued and unpaid interest, were exchanged for newly-issued shares of Common Stock at an exchange rate of 138.8889 shares per $1,000 principal amount of notes, for an exchange price of $7.20 per share. This resulted in the issuance of 5,126,534 shares of Common Stock to ROS Acquisition and 2,905,396 shares of Common Stock to ORO II. On February 14, 2018, ROS Acquisition and ORO II purchased an aggregate of 945,819 shares of Common Stock at a price of $7.20 per share in a private placement. /s/ Carl D. O'Connell, Attorney-in-Fact 2018-02-26